Treatment-resistant schizophrenia (TRS) represents a major clinical challenge. The broad
definition of TRS requires nonresponse to at least 2 sequential antipsychotic trials of …

Abstract Treatment-resistant schizophrenia (TRS) will affect about one in three patients with
schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be …

Current medications for schizophrenia typically modulate dopaminergic neurotransmission.
While affecting positive symptoms, antipsychotic drugs have little clinical effect on negative …

Schizophrenia is a brain disorder that profoundly perturbs cognitive processing. Despite the
success in treating many of its symptoms, the field lacks effective methods to measure and …

Behavioural supersensitivity may be a result of increased glutamate sensitivity of D2-MSN
and reduced sensitivity to dopamine. We propose that clozapine may address behavioural …

Around a quarter of people who experience a first episode of psychosis (FEP) will develop
treatment-resistant schizophrenia, but there are currently no established clinically useful …

Background: Treatment-resistant schizophrenia is prevalent and difficult to manage, as
patients fail multiple antipsychotic trials before being considered as treatment-resistant …

Antipsychotic treatment resistance affects up to a third of individuals with schizophrenia. Of
those affected, 70–84% are reported to be treatment resistant from the outset. This raises the …

Objectives: To determine the prevalence and correlates of treatment-resistant schizophrenia
(TRS) through a systematic review and meta-analysis. Methods: Following Preferred …

This systematic review aimed to review neuroimaging studies comparing clozapine-resistant
schizophrenia patients with clozapine-responding patients, and with first-line antipsychotic …